Category Archives: Cancer Treatment

Oncotarget: A Reliable Resource for Cancer Related Information

Mikhail Blagosklonny and Andrei V. Gudkov created an online medical journal that is now being used by the majority of scientists around the world because of its reliability and convenience. They also serve as the online medical journal’s editors in chief, responsible for reviewing every article that is being submitted by contributors around the world. They named their online medical journal as Oncotarget, because it initially requested information about cancer from the contributors, who are mostly oncologists, but since 2017, there are other scholarly articles found on the online medical journal that tackles about other deadly diseases, and it is no longer focused on articles about cancer alone. Oncotarget is also known as the first peer-reviewed online medical journal, which means that a panel of scientists is reviewing each article that is being sent to Oncotarget. It allows the online medical journal to have a collection of high-quality articles that tackles about fatal human diseases. Learn more about Oncotarget at Research Gate.

 

In 2010, Mikhail Blagosklonny and Andrei V. Gudkov had a conversation about creating a system that would enable oncologists from around the world to meet up in a virtual platform where they can share their ideas. They started to think about creating a website, which would, later on, be referred to as Oncotarget, and they managed to get a lot of readers from around the world after the online medical journal was launched. The names Mikhail Blagosklonny and Andrei V. Gudkov became well-known among the scientific community because of their creation. After making it live, scientists from around the world now have the chance to send what they know about cancer and other fatal diseases to the system’s database, and it will be reviewed by the scientific community. If the articles made it through the selection process, other scientists from around the world would be able to access the document using only a computer and a personal computer.

Listen: https://soundcloud.com/oncotarget

The invention of Mikhail Blagosklonny and Andrei V. Gudkov made sharing and brainstorming ideas among the scientists an easy task, and it is seen as the future of communication and medicine, where the two industries will integrate for the benefit of humankind. Follow Oncotarget journal on Twitter.

Clay Siegall Is Kicking Cancers Butt

In a recent interview with Inspirey.com, founder and CEO of Seattle Genetics sat down to share his some of his secrets to success. Always passionate about helping others, Clay Siegall says he has always had a passion for medicine. The desire to fight illness and help others overcome disease is what led the entrepreneur to create Seattle Genetics.

After watching a loved one battle cancer first hand, Siegall was determined to make a difference and revolutionize the cancer treatment industry. Treatment is meant to help improve the quality of life, but Siegall recalls a worsening of his loved one’s condition following the start of treatment. As in most cases, the chemotherapy had also made the symptoms of the patient’s condition worse.

Fueled by the desire to make a change, he began researching other treatment options. To his surprise, the options seemed to be few and were not accessible to all patients. Seattle Genetics was not only created to improve the quality of cancer treatment but to also bridge the gap between proper education and diverse treatment options. Seattle Genetics uses a combination of monoclonal antibody-based therapies and anti-drug conjugates, or ACDs to help patients fight cancer. Unlike chemotherapy, ACDs target only the cells that cause cancer thus reducing the effects of toxins released during traditional chemotherapy.

After graduating from the University of Maryland with a bachelors degree in zoology, Sigeall went on to earn a Ph.D. in genetics from The George Washington University. His combination of compassion and education would serve as fuel in his fight to improve cancer treatment. The company’s newest development, brentuximab vedotin or ADCETRIS is making a breakthrough in the cancer treatment industry. Under the guidance of Dr. Clay Siegall, Seattle Genetics has established themselves as leaders in cancer treatment, and in healthcare. Currently, there are more than 20 new ACDs using Seattle Genetics technology in the clinical development stages. Since their 1998 launch, the company has raised more than $675 million towards research and the development of new treatment therapies.